Clinical Trial Results:
Clinical trial to determine the effect of Famciclovir on Epstein-Barr virus activity as measured by EBV shedding in saliva of patients with Multiple Sclerosis.
Summary
|
|
EudraCT number |
2019-000169-19 |
Trial protocol |
GB |
Global end of trial date |
10 Apr 2023
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Nov 2024
|
First version publication date |
07 Nov 2024
|
Other versions |
|
Summary report(s) |
Accepted paper Protocol |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
249627 v5
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT05283551 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Queen Mary University of London
|
||
Sponsor organisation address |
Mile End Road, London, United Kingdom, E1 4NS
|
||
Public contact |
Dr Mays Jawad, Queen Mary University London, 0044 02078827260, research.governance@qmul.ac.uk
|
||
Scientific contact |
Dr Mays Jawad, Queen Mary University London, 0044 02078827260, research.governance@qmul.ac.uk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
07 Jun 2023
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
10 Apr 2023
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
10 Apr 2023
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary aim of this study is to explore the effect of famciclovir (500mg twice daily) on Epstein Barr virus shedding in the saliva of people with MS.
|
||
Protection of trial subjects |
Standard
|
||
Background therapy |
- | ||
Evidence for comparator |
N/A | ||
Actual start date of recruitment |
01 Jun 2019
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 30
|
||
Worldwide total number of subjects |
30
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
29
|
||
From 65 to 84 years |
1
|
||
85 years and over |
0
|
|
|||||||||||||
Recruitment
|
|||||||||||||
Recruitment details |
Recruited as per protocol | ||||||||||||
Pre-assignment
|
|||||||||||||
Screening details |
Screening as per protocol | ||||||||||||
Period 1
|
|||||||||||||
Period 1 title |
Pre drug
|
||||||||||||
Is this the baseline period? |
Yes | ||||||||||||
Allocation method |
Not applicable
|
||||||||||||
Blinding used |
Not blinded | ||||||||||||
Blinding implementation details |
Single arm internal case control design - pre drug
|
||||||||||||
Arms
|
|||||||||||||
Arm title
|
Study population | ||||||||||||
Arm description |
Entire study population | ||||||||||||
Arm type |
pre drug | ||||||||||||
Investigational medicinal product name |
NONE
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Not assigned
|
||||||||||||
Routes of administration |
Not mentioned
|
||||||||||||
Dosage and administration details |
NO DRUG GIVEN
|
||||||||||||
|
|||||||||||||
Period 2
|
|||||||||||||
Period 2 title |
On drug
|
||||||||||||
Is this the baseline period? |
No | ||||||||||||
Allocation method |
Not applicable
|
||||||||||||
Blinding used |
Not blinded | ||||||||||||
Blinding implementation details |
Single arm internal control design
|
||||||||||||
Arms
|
|||||||||||||
Arm title
|
Trial population | ||||||||||||
Arm description |
Entire study population | ||||||||||||
Arm type |
Experimental | ||||||||||||
Investigational medicinal product name |
famciclovir
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||
Routes of administration |
Oral use
|
||||||||||||
Dosage and administration details |
500mg twice daily oral
|
||||||||||||
|
|||||||||||||
Period 3
|
|||||||||||||
Period 3 title |
Post drug
|
||||||||||||
Is this the baseline period? |
No | ||||||||||||
Allocation method |
Not applicable
|
||||||||||||
Blinding used |
Not blinded | ||||||||||||
Blinding implementation details |
Single arm internal control design
|
||||||||||||
Arms
|
|||||||||||||
Arm title
|
Study population | ||||||||||||
Arm description |
Entire study population | ||||||||||||
Arm type |
No intervention | ||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||
|
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Study population
|
||
Reporting group description |
Entire study population | ||
Reporting group title |
Trial population
|
||
Reporting group description |
Entire study population | ||
Reporting group title |
Study population
|
||
Reporting group description |
Entire study population |
|
|||||||||||||||||||||||||
End point title |
Salivary EBV DNA shedding | ||||||||||||||||||||||||
End point description |
Viral shedding was defined as a salivary EBV concentration greater than 5.8 copies/ul, with viral presence defined as any detectable EBV DNA in saliva. The number of samples in each epoch with (a) viral shedding, and (b) viral presence, were recorded as a proportion of total samples
|
||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||
End point timeframe |
During study
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Notes [1] - those with at least one sample meeting QC requirements available across all epochs [2] - those with at least one sample meeting QC requirements available across all epochs [3] - those with at least one sample meeting QC requirements available across all epochs |
|||||||||||||||||||||||||
Statistical analysis title |
Primary outcome measure | ||||||||||||||||||||||||
Statistical analysis description |
The primary outcome measure, the rate of EBV shedding in saliva, was assessed as a proportion in the pre-treatment and the on-treatment epochs. As the on-treatment groups were expected to be skewed, paired proportions were compared using the Wilcoxon Signed-Rank Test.
|
||||||||||||||||||||||||
Comparison groups |
Study population v Trial population v Study population
|
||||||||||||||||||||||||
Number of subjects included in analysis |
63
|
||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||
Analysis type |
superiority [4] | ||||||||||||||||||||||||
P-value |
< 0.05 | ||||||||||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||
Notes [4] - As above |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From trial initiation until EoT
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
29
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Entire study population
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Entire study population | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal. Justification: Only females could be exposed to this AE given gender-specific AE (Uterine polypectomy). Of 30 participants, 19 were female (please see page 2 of "Accepted paper/FamV paper_v3_revised_clean.docx" in "Summary attachments" section. 1 subject was affected out of 19 female subjects that could be exposed to an Uterine polypectomy. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||
Substantial protocol amendments (globally) |
|||||||
Were there any global substantial amendments to the protocol? No | |||||||
Interruptions (globally) |
|||||||
Were there any global interruptions to the trial? Yes | |||||||
|
|||||||
Limitations and caveats |
|||||||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||||||
None reported |